Tagged Articles

inflammatory pancreatic effects 2 articles

Type 2 diabetes drug does not reduce risk of heart attack, stroke, death

Diabetes drug Onglyza (saxagliptin) does not reduce the risk of heart attacks, strokes or death from cardiovascular causes compared to a placebo, drug makers Bristol Myers Squibb and AstraZeneca said. The companies had conducted clinical trials to determine if the Type 2 diabetes treatment could help reduce the risk of non-fatal heart attacks and ischemic strokes and death from cardiovascular problems as well as lower blood glucose levels. Onglyza did not perform better than a placebo; however, it was not inferior to the placebo either. The clinical trials involved 16,500 people with diabetes as well as a history of heart ... Read More

Class of type 2 diabetes drugs linked to acute pancreatitis, pancreatic cancer, thyroid cancer

Concerns over the safety of a class of type 2 diabetes drugs known as incretin mimetics – glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors – took a sharp turn recently after an investigative report by British media revealed that it uncovered unpublished data that links the drugs to “unwanted proliferative or inflammatory pancreatic effects,” and that drug regulators in the United States and Europe have not responded quickly enough to studies that suggest these drugs are not as safe as manufacturers claim. Incretin mimetic drugs include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, ... Read More